部分流量储备
医学
心脏病学
血运重建
冠状动脉血流储备
内科学
心肌梗塞
临床终点
冠状动脉疾病
临床试验
冠状动脉造影
作者
Nils P. Johnson,Hitoshi Matsuo,Masafumi Nakayama,Ashkan Eftekhari,Tsunekazu Kakuta,Nobuhiro Tanaka,Evald Høj Christiansen,Richard L. Kirkeeide,K. Lance Gould
标识
DOI:10.1016/j.jcin.2021.07.041
摘要
OBJECTIVES The aim of this study was to assess clinical outcomes after combined pressure and flow assessment of coronary lesions.BACKGROUND Although fractional flow reserve (FFR) remains the invasive reference standard for revascularization, approximately 40% of stenoses have discordant coronary flow reserve (CFR).Optimal treatment for these disagreements remains unclear.METHODS A total of 455 subjects with 668 lesions were enrolled from 12 sites in 6 countries.Only lesions with reduced FFR and CFR underwent revascularization; all other combinations received initial medical therapy.RESULTS Fourteen percent of lesions had FFR #0.8 but CFR $2.0 while 23% of lesions had FFR >0.8 but CFR <2.0.During 2-year follow-up, the primary endpoint of composite all-cause death, myocardial infarction, and revascularization in lesions with FFR #0.8 but CFR $2.0 (10.8% event rate) compared with lesions with FFR >0.8 and CFR $2.0 (6.2% event rate) exceeded the prespecified þ10% noninferiority margin (P ¼ 0.090).Target vessel failure models using both continuous FFR and continuous CFR found that only higher FFR was associated with reduced target vessel failure (Cox P ¼ 0.007) after initial medical treatment.Central core laboratory review accepted 69.8% of all tracings with mean differences of <0.01 for FFR and <0.02 for CFR, indicating no material impact on clinical measurements or outcomes.CONCLUSIONS All-cause death, myocardial infarction, and revascularization after 2 years was not noninferior between lesions with FFR #0.8 but CFR $2.0 and lesions with FFR >0.8 and CFR $2.0.These results do not support using invasive CFR $2.0 to defer revascularization for lesions with reduced FFR if the patient would otherwise be a candidate on the basis of the entire clinical scenario and treatment preference.(
科研通智能强力驱动
Strongly Powered by AbleSci AI